Clinical Trials Logo

Castration-Resistant Prostate Cancer clinical trials

View clinical trials related to Castration-Resistant Prostate Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 5

NCT ID: NCT02312557 Active, not recruiting - Clinical trials for Castration-Resistant Prostate Carcinoma

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Start date: November 18, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with prostate cancer that has spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels despite previous treatment with enzalutamide. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells.

NCT ID: NCT02099864 Active, not recruiting - Clinical trials for Castration-Resistant Prostate Carcinoma

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

Start date: February 5, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body. Studying samples of tissue and blood in the laboratory from patients with prostate cancer may help doctors better understand castration-resistant prostate cancer. It may also help doctors make improvements in prostate cancer treatment.

NCT ID: NCT02025010 Active, not recruiting - Clinical trials for Castration-resistant Prostate Cancer

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

Start date: January 27, 2014
Phase: Phase 2
Study type: Interventional

This study is comparing the safety and effectiveness of abiraterone acetate alone, followed by the addition of prednisone (when the participant's disease worsens or the physician feels it would lessen symptoms of toxicity) versus the current approved treatment regimen which involves the concomitant use of prednisone in conjunction with abiraterone acetate. Additionally, this study is also examining why participants stop responding to treatment with abiraterone acetate by evaluating blood and tissue.